Our Pricing

Wegovy Injection Doses with Exclusive Discount Code WEIGHTLOSSNEW

Published on: June 03, 2026

Searching for wegovy injection doses discount code uk options? Cured Pharmacy offers genuine UK-licensed Wegovy (semaglutide) from £79.00 with discount code WEIGHTLOSSNEW, including free clinical assessment by our UK-registered prescribers and 100% discreet packaging. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets MHRA standards.

Understanding Wegovy Injection Doses and Titration

Wegovy is available in five distinct dose strengths: 0.25mg, 0.5mg, 1mg, 1.7mg, and the maintenance dose of 2.4mg. The treatment follows a carefully designed dose escalation schedule approved by the MHRA to minimise gastrointestinal side effects whilst optimising weight loss outcomes [1].

The standard titration protocol begins with 0.25mg once weekly for four weeks, then increases to 0.5mg for four weeks, 1mg for four weeks, 1.7mg for four weeks, and finally the maintenance dose of 2.4mg weekly. This gradual escalation allows your body to adapt to semaglutide's effects on GLP-1 receptors, which regulate appetite and glucose metabolism [1][2].

In the STEP 1 clinical trial, participants following this dose escalation achieved an average 14.9% body weight reduction over 68 weeks when combined with lifestyle intervention — significantly higher than the 2.4% seen with placebo [2]. Your UK prescriber will determine the appropriate starting dose based on your medical history and current medications during your free online consultation.

What If I Miss a Dose?

If you miss your weekly Wegovy injection and it's been less than five days since your scheduled dose, take it as soon as you remember. If more than five days have passed, skip that dose entirely and resume your normal schedule with the next injection [3]. Never double up doses to compensate for a missed injection, as this increases the risk of gastrointestinal side effects like nausea and vomiting.

How to Use Your Wegovy Discount Code WEIGHTLOSSNEW

At Cured Pharmacy, we've made accessing Wegovy straightforward and affordable. Use discount code WEIGHTLOSSNEW during checkout to receive £20 off first order using code WEIGHTLOSSNEW

The process takes under three minutes: complete our free online medical assessment, receive a clinical review from a UK-registered prescriber, and if approved, your prescription is dispensed by our GPhC-registered pharmacy (9012511) with discreet next-day delivery available. All Wegovy pens are genuine UK-licensed medicines sourced directly from licensed wholesalers.

Why Choose Cured Pharmacy for Wegovy

We guarantee the lowest prices in the UK for genuine Wegovy injection doses. Our superintendent pharmacist Tarun Kumar oversees every prescription to ensure safety and compliance with MHRA regulations. You'll never pay for a consultation — our clinical assessments are completely free, and you only pay if your prescription is approved and you choose to proceed.

Wegovy Clinical Evidence and Expected Results

Semaglutide 2.4mg (Wegovy) has been extensively studied across the STEP clinical trial programme involving over 4,500 participants. The landmark STEP 1 trial demonstrated that 86.4% of participants achieved at least 5% weight loss, whilst 69.1% achieved at least 10% weight loss, and 50.5% achieved at least 15% weight loss over 68 weeks [2].

Wegovy works by mimicking GLP-1, a naturally occurring hormone that regulates appetite and food intake. It slows gastric emptying, increases feelings of fullness, and reduces hunger signals in the brain. These mechanisms combine to create a substantial caloric deficit when paired with dietary modifications [1][2].

Results vary between individuals and depend on adherence to the prescribed dose escalation schedule, dietary changes, and physical activity levels. Clinical trials showed the greatest weight loss occurred in participants who combined Wegovy with a reduced-calorie diet and increased physical activity. Your UK prescriber will discuss realistic expectations during your consultation.

Common Side Effects and How to Manage Them

The most frequently reported side effects with Wegovy are gastrointestinal: nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%) in clinical trials [2]. These effects are typically mild to moderate and decrease over time as your body adjusts to each dose level.

To minimise nausea, eat smaller, more frequent meals rather than large portions. Avoid high-fat, greasy, or spicy foods, especially during the first few weeks after each dose increase. Stay well-hydrated and consider taking your injection in the evening so any initial nausea occurs whilst you're sleeping.

Serious side effects are rare but include pancreatitis, gallbladder problems, and hypoglycaemia (particularly if you're taking other diabetes medications). Contact your prescriber immediately if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3].

Wegovy Injection Doses vs Other Weight Loss Treatments

Wegovy (semaglutide 2.4mg) belongs to the GLP-1 receptor agonist class, the most effective pharmacological option currently licensed in the UK for chronic weight management. Other treatments in this category include Saxenda (liraglutide), which requires daily injections, and Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist showing even greater weight loss in head-to-head trials [4].

Oral options like Orlistat (Xenical) and Mysimba work through different mechanisms — Orlistat blocks fat absorption in the gut, whilst Mysimba combines naltrexone and bupropion to reduce appetite. These typically produce more modest weight loss (5-10% body weight) compared to injectable GLP-1 treatments [5].

Your choice between treatments depends on several factors: injection frequency preference, previous treatment response, contraindications, and budget. All prescription weight loss medications available at Cured Pharmacy require ongoing lifestyle modification and are intended for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities, in line with NICE guidance.

Switching Between Weight Loss Treatments

If you're currently taking Saxenda or considering switching from Wegovy to Mounjaro, your UK prescriber will create a safe transition plan. Generally, you'll stop one medication and begin the new treatment at its lowest starting dose to assess tolerance. Never switch between GLP-1 medications without prescriber guidance, as this may increase side effect risk or affect glycaemic control if you have type 2 diabetes.

Long-Term Use and Maintenance with Wegovy Doses

Wegovy is licensed for long-term chronic weight management, not short-term use. Clinical data from the STEP 1 trial extension showed that participants who continued Wegovy 2.4mg maintained their weight loss through 104 weeks, whilst those who discontinued treatment regained approximately two-thirds of their lost weight [6].

Once you reach the maintenance dose of 2.4mg weekly, regular follow-up with your prescriber is essential. At Cured Pharmacy, we recommend reassessment every three months to monitor weight loss progress, adjust dietary and exercise plans, and screen for any emerging side effects or contraindications.

If you experience intolerable side effects at the 2.4mg maintenance dose, your prescriber may reduce you to 1.7mg weekly. Whilst this lower dose produces slightly less weight loss on average, it remains clinically effective and may be better tolerated long-term. The decision to continue, adjust, or discontinue Wegovy should always be made collaboratively with your UK-registered prescriber based on your individual response and health status.

Scientific References

1. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Weight management: lifestyle services for overweight or obese adults. NICE guideline [PH53]. Retrieved from https://www.nice.org.uk/guidance/ph53 [accessed 13 August 2026]
6. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated for weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity. Individual results may vary.